Key facts
- Xeltis’s last known valuation is $107.5M (Jun 2023).
- It has raised $268.6M; the latest was Later Stage VC ($57.8M) in Dec 2025.
- Notable investors include European Innovation Council, Invest-NL (Investment Company), EQT Life Sciences, Kurma Partners, Vi Partners — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Xeltis
- ·The full record, as it builds
Funding rounds
No funding rounds for Xeltis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xeltis
Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioresorbable implants that facilitate bioabsorbable heart valves and blood vessels to stimulate the body to create its natural vessel tissue, enabling doctors to help patients improve their requiring vascular interventions.
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2006
- Employees
- 56
- Website
- xeltis.com/
- Ownership
- Privately Held (backing)
Xeltis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xeltis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xeltis in its N-PORT filings yet. We sweep new filings monthly.